Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 4/20 | 0.43 |
| ▸ | HTR7 | P34969 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26023533 | 0.85 | PGR (0.44) | HTR2BHTR7PGRALDH1A1MEN1 | |
| SCHEMBL18385982 | 0.79 | HTR2B (0.50) | HTR2BHTR7PGRALDH1A1MEN1 | |
| SCHEMBL5523779 | 0.76 | PGR (0.44) | HTR2BHTR7PGRALDH1A1MEN1 | |
| SCHEMBL26631822 | 0.76 | HKDC1 (0.32) | MEN1KMT2AHKDC1HTR2AL3MBTL1 | |
| SCHEMBL30441120 | 0.74 | HTR2B (0.47) | HTR2BHTR7PGRALDH1A1MEN1 | |
| SCHEMBL20082694 | 0.74 | CYP1A2 (0.53) | HTR2BHTR7PGRALDH1A1MEN1 | |
| SCHEMBL1075715 | 0.74 | HTR2B (0.51) | HTR2BHTR7PGRALDH1A1MEN1 | |
| SCHEMBL22336275 | 0.74 | HTR2B (0.47) | HTR2BHTR7PGRALDH1A1MEN1 | |
| SCHEMBL29884836 | 0.74 | MAOA (0.52) | HTR2BHTR7PGRALDH1A1MEN1 | |
| SCHEMBL216862 | 0.74 | MAOA (0.52) | HTR2BHTR7PGRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5663030-A | A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL R&D CO., LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| CN-114981275-B | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-4273150-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273150-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-114981275-A | Tricyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2022143489-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2022-07-07 | — | — | WO | disclosed |
| EP-2277124-B1 | MEANS FOR TREATING MYOSIN-RELATED DISEASES | HANNOVER MED HOCHSCHULE (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-8536242-B2 | Photocurable composition | SEKISUI CHEMICAL CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-20110105554-A1 | MEANS FOR TREATING MYOSIN-RELATED DISEASES | KINARIS BIOMEDICALS GMBH (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110097669-A1 | PHOTOCURABLE COMPOSITION | SEKISUI CHEMICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| EP-2277124-A2 | MEANS FOR TREATING MYOSIN-RELATED DISEASES | KINARIS Biomedicals GmbH (DE) | 2011-01-26 | — | — | EP | disclosed |
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | SHOICHET BRIAN K | 2009-12-24 | — | — | US | disclosed |
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | SHOICHET BRIAN K | 2009-12-24 | — | — | US | disclosed |
| US-7541381-B2 | Non-covalent inhibitors of AmpC β-lactamase | NORTHWESTERN UNIVERSITY (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541381-B2 | Non-covalent inhibitors of AmpC β-lactamase | NORTHWESTERN UNIVERSITY (US) | 2009-06-02 | — | — | US | disclosed |
| WO-2009065600-A2 | MEANS FOR TREATING MYOSIN-RELATED DISEASES | Technische Universität Dresden (DE) | 2009-05-28 | — | — | WO | disclosed |
| US-20070072096-A1 | Negative curable dye-containing composition, color filter, and method of manufacturing the same | FUJI PHOTO FILM CO., LTD. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318711-A1 | Non-Covalent Inhibitors of AmpC ß-Lactamase | AMPD1, AMPD2, AMPD3 | HTR2B 4470/4885HTR7 4837/4885PGR 4711/4885 |
| US-20110105554-A1 | MEANS FOR TREATING MYOSIN-RELATED DISEASES | MYH14, MYH2, MYLK2 | HTR2B 3314/4885HTR7 2648/4885PGR 4453/4885 |
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GOT2, HADH, CYP4A11 | HTR2B 1543/4885HTR7 584/4885PGR 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.